Literature DB >> 11125847

Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.

W K Chan1, A B Delucchi.   

Abstract

Resveratrol, a phytoalexin found in red wine, has been shown to possess antioxidant and antimutagenic properties. Incubation of resveratrol with Sf9 insect microsomes containing baculovirus-derived human cytochrome P450 3A4 (CYP3A4) and NADPH-cytochrome P450 reductase showed that resveratrol inactivated CYP3A4 in a time- and NADPH-dependent manner. Resveratrol, erythromycin and troleandomycin inactivated CYP3A4 at a similar rate (as reflected by k(inact)) whereas the binding affinity to CYP3A4 (as reflected by K(I)) was in the order of: troleandomycin > erythromycin > resveratrol. (K(I) and k(inact) for CYP3A4 inactivation by resveratrol, erythromycin and troleandomycin are 20 microM and 0.20 min(-1), 5.3 microM and 0.12 min(-1) and 0.18 microM and 0.15 min(-1), respectively.) Fractionation studies of red wine showed that fractions that did not contain resveratrol inactivated CYP3A4 significantly. In addition, the resveratrol content in red wine used in the study was too low to account for the degree of CYP3A4 inactivation observed after red wine treatment. Inactivation studies using a variety of red wine types showed that the CYP3A4 inactivation did not correlate to their resveratrol content. In summary, data here showed that resveratrol is an effective mechanism-based inactivator of CYP3A4; however, it is not one of the main red wine constituents that are responsible for CYP3A4 inactivation by red wine. Nevertheless, inactivation of CYP3A4 by resveratrol may cause clinically relevant drug interactions with CYP3A4 substrates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11125847     DOI: 10.1016/s0024-3205(00)00888-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  26 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.

Authors:  Yitong Liu; Thomas J Flynn; Menghang Xia; Paddy L Wiesenfeld; Martine S Ferguson
Journal:  Cell Biol Toxicol       Date:  2015-09-16       Impact factor: 6.691

3.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

4.  The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.

Authors:  Motohiro Kato; Yoshihisa Shitara; Hitoshi Sato; Kunihiro Yoshisue; Masaru Hirano; Toshihiko Ikeda; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-05-16       Impact factor: 4.200

Review 5.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

Review 6.  Biochemical effects of SIRT1 activators.

Authors:  Joseph A Baur
Journal:  Biochim Biophys Acta       Date:  2009-11-06

Review 7.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

Review 8.  Critical review of resveratrol in xenobiotic-induced hepatotoxicity.

Authors:  Mitchell R McGill; Kuo Du; James L Weemhoff; Hartmut Jaeschke
Journal:  Food Chem Toxicol       Date:  2015-11-10       Impact factor: 6.023

Review 9.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model.

Authors:  Hui-ling Yang; Wei-qiong Chen; Xuan Cao; Andrea Worschech; Li-fen Du; Wei-yi Fang; Yang-yan Xu; David F Stroncek; Xin Li; Ena Wang; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-03-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.